PRA SEC Filings - Proassurance Cp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive list of SEC filings for ProAssurance Corporation (PRA), including 10-K, 10-Q, and 8-K forms, alongside AI-generated summaries and sentiment analysis. Recent filings detail equity compensation awards to executives, cash incentive approvals related to an upcoming merger with The Doctors Company, and Q3 2025 financial results. Key financial data, such as EPS, net income, revenues, and merger progress, are highlighted, with the company anticipating a merger closing by June 30, 2026.
ProAssurance Reports Results for Fourth Quarter and Full-Year 2025
ProAssurance Corporation reported net income of $33.4 million for Q4 2025 and $50.9 million for the full year 2025, with operating income reaching $42.4 million and $83.9 million, respectively. The company highlighted progress in achieving appropriate premium rates, particularly in medical professional liability, and noted an 8.3% increase in net investment income. ProAssurance also provided updates on its pending transaction with The Doctors Company, anticipating a closing by June 30, 2026, subject to regulatory approvals.
Form 13D/A PROASSURANCE CORPORATION For: 30 June By Investing.com
This article announces the filing of Form 13D/A for PROASSURANCE CORPORATION, specifically for the period ending June 30. The content is brief and primarily serves as a notice, with the main body consisting of the headline repeated several times and links to other financial news and market data.
Magnetar funds exit ProAssurance (PRA) after $25-per-share cash merger
Magnetar Financial, Magnetar Capital Partners, Supernova Management, and David J. Snyderman have filed an exit Schedule 13D/A, confirming they no longer beneficially own shares of ProAssurance Corporation (PRA). This follows a merger on June 26, 2026, where each ProAssurance share was converted into $25.00 in cash, resulting in the cancellation of Magnetar's 2,615,966 shares. Prior to this, Magnetar had made additional purchases of 53,990 shares in the 60 days leading up to the merger.
Form 13D/A PROASSURANCE CORPORATION For: 30 June By Investing.com
This article announces the filing of Form 13D/A for PROASSURANCE CORPORATION, specifically noting it is "For: 30 June". The brief content provides the filing information without further details or analysis. The filing is presented as a stock market update from Investing.com.
The Doctors Company completes acquisition of ProAssurance
The Doctors Company has completed its acquisition of ProAssurance Corporation, making it the top U.S. writer of physicians' and surgeons' medical professional liability coverage. This integration increases The Doctors Company's assets to $12 billion, protecting over 200,000 healthcare professionals and strengthening its resources and advocacy for the medical profession. The Michigan State Medical Society (MSMS) Physicians Insurance Agency highlighted this development, as TDC is their exclusive endorsed professional liability carrier.
EMPLOYERS names Jeffrey Lisenby as general counsel
EMPLOYERS has appointed Jeffrey Lisenby as executive vice president and general counsel. Lisenby previously spent 25 years in a similar role at ProAssurance Corporation, bringing extensive experience in insurance law and regulatory matters. His appointment comes as EMPLOYERS navigates a challenging underwriting environment and expands its product offerings, requiring robust legal and regulatory expertise.
Business Moves: The Doctors Co. Completes Buy of ProAssurance
The Doctors Company has completed its acquisition of ProAssurance Corporation for approximately $1.3 billion. This merger creates a combined entity with $12 billion in assets, aiming to be a leading medical professional liability and specialty lines insurer in America. ProAssurance's stock has been delisted, and it now operates as a wholly-owned subsidiary of The Doctors Company.
The Doctors Company closes $1.3 billion ProAssurance acquisition
The Doctors Company has completed its $1.3 billion acquisition of ProAssurance Corporation, creating one of the largest medical professional liability insurers in the US with $12 billion in assets. This merger addresses the intensifying pressures on the US medical malpractice market, including rising premiums and "nuclear malpractice verdicts." The deal will allow the combined entity to leverage deeper reserves and broader reinsurance relationships to manage escalating claims.
ProAssurance Corporation(NYSE:PRA) dropped from S&P Composite 1500
ProAssurance Corporation (NYSE:PRA) has been removed from the S&P Composite 1500 index. This news follows a series of other index removals, including from various Russell benchmarks, and comes shortly after The Doctors Company completed its acquisition of ProAssurance Corporation. The company, an insurance holding entity, specializes in medical professional liability, medical technology liability, and workers' compensation insurance.
Enterprise value to EBIT forward of ProAssurance Corporation – LS:676103
The article focuses on the enterprise value to EBIT forward of ProAssurance Corporation (LS:676103). It appears to be a financial data page from TradingView, offering an overview of the company's financial metrics. The main content indicates the period and value of this specific financial ratio for ProAssurance Corporation.
ProAssurance Corporation Financial Disclosures & Filings
This page provides access to ProAssurance Corporation's (PRK) financial disclosures and regulatory filings, including quarterly and annual earnings releases and reports. Investors can explore 8-K, 10-Q, and 10-K documents, as well as call transcripts, dating back to 2015 to support informed investment decisions. The documents offer insights into the company's performance and strategy.
Price to earnings forward of ProAssurance Corporation – FWB:PRK
This page provides financial information for ProAssurance Corporation (PRK) on the Frankfurt Stock Exchange. It specifically highlights the "Price to earnings forward" metric for the company. The page appears to be a financial data presentation from TradingView.
Price to book forward of ProAssurance Corporation – LS:676103
This article provides financial information for ProAssurance Corporation (LS:676103) on TradingView, specifically focusing on its "Price to book forward" metric. The page includes general market data, an overview of the company's financials, and indicates that the market was closed with no trades at the time of viewing.
Price to earnings forward of ProAssurance Corporation – LS:676103
This article provides a brief financial overview of ProAssurance Corporation (LS:676103) focusing on its price-to-earnings forward metric. The content indicates that the market is currently closed with no trades, and the financial data is sourced from ICE Data Services and FactSet.
ProAssurance (PRA) director’s 10,621 shares cashed out in merger
ProAssurance (PRA) director Staci Pierce disposed of 10,621 shares of common stock as part of the company's merger agreement with The Doctors Company. The shares were cancelled and converted into cash at $25.00 per share on June 26, 2026. Following this transaction, Pierce no longer holds any ProAssurance common stock.
Press Release: The Doctors Company Completes Acquisition of ProAssurance Corporation
The Doctors Company has successfully completed its acquisition of ProAssurance Corporation, finalizing the merger after an all-cash tender offer for ProAssurance's common stock. This strategic transaction aims to enhance The Doctors Company's position as a leading physician-owned medical malpractice insurer and provides ProAssurance shareholders with significant value while ensuring continued service for their policyholders.
ProAssurance (NYSE: PRA) bought for cash as The Doctors Company closes deal
ProAssurance Corporation completed its merger with The Doctors Company, converting all outstanding shares of ProAssurance common stock into the right to receive $25.00 in cash per share, without interest. ProAssurance is now a wholly-owned subsidiary of The Doctors Company, and its shares will be delisted from the NYSE, ceasing public trading and reporting obligations. The transaction also included the settlement of equity-based awards in cash, termination of the company's credit agreement, and a complete change in its board and management.
The Doctors Company Completes $1.3 Billion Acquisition Of ProAssurance
The Doctors Company has completed its acquisition of ProAssurance Corporation for approximately $1.3 billion, buying all outstanding shares for $25.00 per share in cash. This merger creates a combined entity that will safeguard over 200,000 healthcare professionals and organizations, holding $12 billion in assets. ProAssurance will operate as a wholly-owned subsidiary, reinforcing The Doctors Company's mission to support healthcare professionals through expanded advocacy, service, and stability.
The Doctors Company Completes $1.3 Billion Acquisition of ProAssurance
The Doctors Company has finalized its $1.3 billion acquisition of ProAssurance Corporation (NYSE: PRA), forming a leading provider of medical professional liability and specialty insurance with over $12 billion in assets. This strategic move expands The Doctors Company's market presence and combines its physician-owned model with ProAssurance's underwriting expertise to address the evolving complexities of healthcare risks. ProAssurance will operate as a wholly owned subsidiary, and its stock will be delisted from the NYSE.
The Doctors Company Completes Acquisition of ProAssurance Corporation
The Doctors Company has completed its acquisition of ProAssurance Corporation, integrating the two medical professional liability insurance providers. This transaction, finalized on Friday, June 26, 2026, consolidates their operations and expands The Doctors Company's presence in the medical malpractice insurance sector. Both companies will now operate as a combined organization following the fulfillment of all regulatory requirements.
The Doctors Company acquires ProAssurance for $1.3B, creating a $12B medical malpractice insurer.
The Doctors Company, the largest physician-owned medical malpractice insurer in the U.S., has acquired ProAssurance Corporation for approximately $1.3 billion in cash. This merger creates a combined entity with $12 billion in assets, covering over 200,000 healthcare professionals and organizations. ProAssurance will initially operate as a wholly owned subsidiary, with the acquisition strengthening the combined company's position in medical liability and specialty insurance markets.
Doctors Company completes ProAssurance acquisition for $1.3B By Investing.com
The Doctors Company has finalized its acquisition of ProAssurance Corporation for approximately $1.3 billion, paying $25.00 per share in cash. ProAssurance will operate as a wholly owned subsidiary of The Doctors Company, and its stock has been delisted from the NYSE. This merger creates a combined entity with $12 billion in assets, serving over 200,000 healthcare professionals.
The Doctors Company buys ProAssurance, creating a $12B insurer
The Doctors Company has completed its acquisition of ProAssurance for $25.00 per share in cash, valuing the transaction at approximately $1.3 billion. The combined entity will protect over 200,000 healthcare professionals and organizations and hold $12 billion in assets. ProAssurance will be delisted from the NYSE and operate as a wholly-owned subsidiary.
ProAssurance Corp stock hits 52-week high at $24.99
ProAssurance Corp (PRA) stock reached a 52-week high of $24.99, indicating investor confidence and positive market conditions with a 7.88% gain over the past year. Despite appearing overvalued compared to its Fair Value estimate according to InvestingPro, its PEG ratio of 0.37 suggests an attractive valuation relative to growth expectations. This milestone follows recent regulatory approval for its merger with The Doctors Company, where ProAssurance will become a wholly owned subsidiary.
ProAssurance receives final regulatory approval for merger with The Doctors Company
ProAssurance (NYSE:PRA) announced it has received all necessary regulatory approvals for its merger with The Doctors Company. The merger, initially disclosed in March 2025, will make ProAssurance a wholly-owned subsidiary of The Doctors Company, with closing expected on June 26, 2026. The stock is currently trading near its 52-week high, and InvestingPro analysis suggests it may be overvalued.
ProAssurance Corp stock hits 52-week high at $24.99 By Investing.com
ProAssurance Corp (PRA) stock has reached a new 52-week high of $24.99, demonstrating a 7.88% positive change over the past year. The company, which has a market capitalization of $1.27 billion and a P/E ratio of 19.6, is trading near its fair value according to InvestingPro analysis, with a PEG ratio of 0.37 suggesting attractive valuation. This milestone follows recent regulatory approval for its merger with The Doctors Company, where ProAssurance will become a wholly owned subsidiary.
ProAssurance receives final regulatory approval for merger with The Doctors Company
ProAssurance Corporation has received all necessary regulatory approvals to complete its merger with The Doctors Company. The stock is trading near its 52-week high, with the merger expected to close on Friday, June 26, 2026. ProAssurance will become a wholly-owned subsidiary of The Doctors Company.
Form 8K ProAssurance Corp For: 23 June By Investing.com
This article reports on ProAssurance Corp's Form 8K filing for June 23, 2026. The brief announcement provides a direct link to the filing for further details and mentions the company's stock symbol PRA. It seems to be a standard regulatory news update from Investing.com.
ProAssurance to close merger with The Doctors Company after receiving all regulatory approvals
ProAssurance (PRA) is set to be acquired by The Doctors Company following the receipt of all necessary regulatory approvals. The merger is expected to close on June 26, 2026, making ProAssurance a wholly owned subsidiary. Stockholders approved the transaction in June 2025, and FTC early termination was granted in July 2025.
All regulatory approvals in for ProAssurance (NYSE: PRA) merger with The Doctors Company
ProAssurance Corporation (NYSE: PRA) has announced that all required regulatory approvals for its merger with The Doctors Company have been secured, including approvals from insurance regulators in all relevant jurisdictions and early termination of the Hart-Scott Rodino antitrust review. ProAssurance stockholders had previously approved the merger on June 24, 2025. The merger is now expected to close on June 26, 2026, at which point ProAssurance will become a wholly owned subsidiary of The Doctors Company, pending the satisfaction of customary closing conditions.
ProAssurance Corp (PRA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a detailed timeline of ProAssurance Corp's (PRA) dividend payouts and stock splits. It lists the dates, dividend amounts, record dates, payment dates, and ex-dividend dates for interim cash dividends, noting that a total of $26.91 million has been distributed over the past five years. The article also indicates that there is no stock split data available for the company.
ProAssurance Corp (PRA) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for ProAssurance Corp (PRA), noting its current earnings forecast score is 5.67, ranking 104 out of 117 in the Insurance industry. Analysts have a consensus "Hold" rating for PRA with an average price target of $25.00. The company's expected revenue for the next quarter is $213.57 million, and EPS for the next quarter is projected at $0.32.
Is ProAssurance (PRA) Overvalued With A 19.3x P/E After Recent Stable Share Price Performance
ProAssurance (PRA) is trading at a P/E ratio of 19.3x, which is considered expensive compared to its peers and the broader US insurance industry. Despite stable recent share price performance and increasing net income, the company's revenue is edging lower, and its P/E multiple is significantly higher than an estimated fair value of 9.8x. This premium valuation may reflect expectations of improving profitability and high-quality earnings rather than top-line growth, but leaves little room for disappointment.
ProAssurance Shares Rise After Saying It Expects Doctors Company Merger to Close by June 30
ProAssurance Corporation's shares rose after the company announced its expectation to close the merger with The Doctors Company by June 30, 2026. This acquisition is significant for ProAssurance, as it will likely impact its market position and financial outlook. Investors reacted positively to the news of the impending completion of this major corporate transaction.
ProAssurance (PRA) nears merger completion as most regulators approve deal
ProAssurance Corporation is nearing the completion of its merger with The Doctors Company, with most regulatory approvals secured. While approvals have been granted in several U.S. states, Lloyd's of London, and the Cayman Islands, the review from California insurance regulators is still pending. Despite the uncertainty regarding California's decision, ProAssurance maintains its target of closing the transaction by June 30, 2026.
ProAssurance expects merger close by June 30, 2026 after regulator approvals in multiple jurisdictions
ProAssurance (PRA) anticipates its merger with The Doctors Company will close by June 30, 2026, as planned. The merger has received necessary approvals in several states, Lloyd's, and Cayman, but regulatory review in California is still pending. The company’s board and stockholders approved the transaction in March and June 2025, respectively, and the FTC granted early HSR termination in July 2025.
ProAssurance Nears Completion of Merger with The Doctors Company
ProAssurance is nearing the completion of its merger with The Doctors Company, with most regulatory approvals secured, except for California's review. The merger, initially agreed upon in March 2025, has progressed through shareholder approvals and other regulatory clearances. Despite the advanced stage, the uncertain timing of the remaining approval introduces ongoing execution risk, with the companies aiming for a June 30, 2026 closing.
Assessing ProAssurance (PRA) Valuation As Shares Trade Near Analyst Targets
ProAssurance (PRA) shares are trading around analyst targets but its P/E ratio of 19.5x appears expensive compared to the insurance industry average of 11.4x and peers' 12.6x. This valuation comes despite recent declines in revenue and net income. Investors should consider the premium valuation, potential for pressure on sentiment due to concentration in specialty insurance, and the current risks and rewards associated with the stock.
How Proassurance Corporation (PRA) Affects Rotational Strategy Timing
This article analyzes Proassurance Corporation (PRA) with a neutral sentiment, indicating sideways action. AI-generated trading strategies are provided for different risk profiles, including long, breakout, and short setups with specific entry, target, and stop-loss levels. The analysis emphasizes a wait-and-see approach due to a mid-channel oscillation pattern and offers a favorable risk-reward for a short setup.
How Proassurance Corporation (PRA) Affects Rotational Strategy Timing
This article analyzes Proassurance Corporation (PRA) with a focus on its impact on rotational strategy timing. It highlights a neutral sentiment across all time horizons, suggesting a wait-and-see approach. The analysis includes AI-generated institutional trading strategies for long, breakout, and short positions, along with multi-timeframe signal analysis and risk-reward ratios for potential trades.
ProAssurance Corporation Common Stock (NY: PRA
This article provides recent news headlines and financial updates for ProAssurance Corporation (NYSE: PRA), including analyst ratings, earnings reports, dividend announcements, and insider filings. It covers news from various sources like Benzinga, The Motley Fool, and Business Wire, primarily focusing on financial performance and corporate actions from late 2022 to mid-2023. The stock is currently trading at 24.51, unchanged as of May 15, 2026.
PRA Technical Analysis & Stock Price Forecast
The technical analysis for Proassurance Corp (PRA) indicates a Neutral overall sentiment as of May 15, 2026. While some momentum indicators like RSI are neutral, MACD and certain moving averages suggest a sell signal for short-term momentum. However, the stock is trading above its 60-day and 200-day moving averages, which can be seen as a long-term bullish sign.
ProAssurance Q1 earnings meet estimates on declining expenses
ProAssurance (PRA) reported its Q1 earnings, meeting estimates primarily due to a reduction in expenses. The company's focus on cost control has positively impacted its financial performance for the quarter. This outcome highlights effective management strategies in lowering operational costs.
Life Insurance In Force of ProAssurance Corporation – NYSE:PRA
This page provides financial data specifically on the "Life Insurance In Force" metric for ProAssurance Corporation (NYSE:PRA). It appears to be a section within a larger financial overview on the TradingView platform. The content primarily lists the company name and stock exchange information, emphasizing its financial performance data accessible via the website.
ProAssurance Q1 Earnings Meet Estimates on Declining Expenses
ProAssurance (PRA) reported Q1 2026 adjusted operating income of 25 cents per share, meeting Zacks Consensus Estimate and increasing from 13 cents last year. Despite a 2.5% dip in operating revenues to $263.1 million, the company benefited from rising investment income and declining expenses, though lower premiums in key segments partially offset gains. Net premiums earned fell by 5.4% year-over-year, but net investment income rose by 8.2%, and total expenses decreased by 9%, leading to a significant 245.3% surge in net income.
ProAssurance (NYSE:PRA) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen has downgraded ProAssurance (NYSE:PRA) from a "hold" to a "sell" rating. Despite this, MarketBeat maintains a consensus "Buy" rating, and Zacks Research recently upgraded the stock to "strong-buy." ProAssurance matched EPS expectations at $0.25, while revenue surpassed forecasts at $262.63 million, and institutional ownership remains high at 85.58%.
Piper Sandler Maintains Proassurance(PRA.US) With Hold Rating, Maintains Target Price $25
Piper Sandler has reiterated its Hold rating for Proassurance (PRA.US), maintaining a target price of $25. This indicates that the firm does not anticipate significant price movement for the stock in the near future. The decision likely reflects their ongoing assessment of the company's financial health and market position.
ProAssurance (PRA) Margin Improvement Reinforces Bullish Narratives Despite Volatile Quarterly EPS
ProAssurance (PRA) reported Q1 2026 revenue of US$262.6 million and basic EPS of US$0.16, with trailing net profit margins improving to 5.9%. While the company shows improved profitability and five-year annualized earnings growth, there are concerns regarding declining trailing revenue, volatile quarterly EPS, and a premium valuation compared to forecasts of future revenue and earnings declines. Investors are evaluating the tension between recent margin gains and a projected slowdown in growth.
ProAssurance's combined ratio improves to 109.9% in Q1
ProAssurance Corporation reported an increase in Q1 operating income to $12.7 million, or $0.25 per diluted share, up from $6.8 million, or $0.13 per diluted share, a year prior. This improvement was driven by better underwriting results and higher investment income for the medical professional liability insurer. The company is currently in the process of being acquired by The Doctors Company.
